生物制药公司Hoth Therapeutics, Inc. (NASDAQ: HOTH )今日宣布，根据与H.C. Wainwright & Co.签订的现有场内发行协议，将其普通股的最高发行总额增加500万美元。自2024年11月8日以来，该公司已根据该协议售出约270万美元的股票。

Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing At ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced ...

Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...

(RTTNews) - Hoth Therapeutics (HOTH), a New York-based biopharmaceutical company, announces IP advancements with expanded patent applications for its therapeutic pipeline. The new patents ...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...